StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

Investment analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Other equities research analysts have also issued reports about the stock. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research report on Tuesday, December 10th.

VolitionRx Stock Down 4.5 %

NYSE VNRX opened at $0.63 on Tuesday. The firm’s 50 day moving average is $0.65 and its 200-day moving average is $0.66. The company has a market capitalization of $58.38 million, a PE ratio of -1.75 and a beta of 1.20. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.23.

Insider Buying and Selling

In related news, Director Guy Archibald Innes acquired 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the acquisition, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Cameron John Reynolds bought 139,811 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were bought at an average price of $0.57 per share, with a total value of $79,692.27. Following the purchase, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. The trade was a 7.07 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 358,266 shares of company stock worth $204,212. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC raised its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.